Turku, Finland – 23rd May, 2024. Clinical-stage drug delivery and development company, DelSiTech Ltd, today announced that the company has entered into a Licensing Agreement with an undisclosed global pharmaceutical company. According to the Licensing Agreement, DelSiTech grants an exclusive global license to DelSiTech’s Silica Matrix based, controlled release technology for development and commercialization of […]
New investment from DRW Venture Capital LLC and Tolmar International Ltd Funds will be used to advance its proprietary, silica-based, drug delivery technology platform towards the clinic and further build DelSiTech Turku, Finland – 16th January 2024. Clinical-stage drug delivery and development company DelSiTech, today announces the successful completion of a EUR 10 million financing round, the […]
Turku, Finland – 29th June 2023: Drug delivery and development company DelSiTech today reported positive topline results from its Phase 1 clinical trial, evaluating the safety and tolerability of DST-2105, DelSiTech’s first of its kind, silica-based, long-acting demulcent eye drop product. Read more…
